The US Food and Drug Administration (FDA) first authorized SAHA (vorinostat) in 2006 as an HDAC inhibitor for the treatment of cancer, but only in patients with cutaneous T-cell lymphoma (CTCL). The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.